Unhappy New Year For Incyte With Itacitinib Flop
JAK1 Inhibitor Fails In Steroid-Naiïve Acute GVHD
Incyte's hopes of reducing its reliance on Jakafi have suffered a blow after a Phase III trial of itacitinib failed. The stock has slumped and analysts are raising concerns about the company's ability to generate value from its hefty R&D investments.
